Skip to main content
PRGO
NYSE Life Sciences

Perrigo Reports Significant Q1 Loss Driven by $330.8M Goodwill Impairment, Reaffirms Full-Year Outlook

Analysis by Arik Shkolnikov
Sentiment info
Negative
Importance info
8
Price
$12.16
Mkt Cap
$1.602B
52W Low
$9.225
52W High
$28.435
Market data snapshot near publication time

summarizeSummary

Perrigo Company plc reported a substantial net loss of $(2.87) per share for Q1 2026, primarily due to a $330.8 million goodwill impairment charge, alongside declining net sales, but reaffirmed its full-year guidance.


check_boxKey Events

  • Q1 Net Loss Reported

    Perrigo reported a net loss of $(398.6) million, or $(2.87) per diluted share, for the first quarter ended March 28, 2026, compared to a net loss of $(6.4) million in the prior year.

  • Significant Goodwill Impairment

    The company recorded a $330.8 million goodwill impairment charge in Q1 2026, which was a primary driver of the reported net loss and was an expected impairment as noted in the prior 10-K.

  • Sales Decline Across Segments

    Reported net sales decreased 7.2% year-over-year to $969.2 million, with Core organic net sales declining 11.0% due to lower consumption and retailer inventory levels in both the U.S. and Europe.

  • Full-Year Outlook Reaffirmed

    Despite the weak first-quarter performance, Perrigo reaffirmed its full-year 2026 outlook, anticipating improvement in the second half of the year from growth initiatives and operational programs.


auto_awesomeAnalysis

Perrigo's first-quarter results reveal significant financial challenges, marked by a substantial net loss and a $330.8 million goodwill impairment, which was anticipated in the prior 10-K. The company experienced declines in both reported and core net sales, reflecting lower consumption and retailer inventory adjustments. Despite these headwinds and increased cash outflow from operations, management has reaffirmed its full-year 2026 outlook, signaling confidence in a second-half improvement driven by growth initiatives and operational enhancements. The completion of the Dermacosmetics business sale, with proceeds directed towards debt reduction, provides some financial flexibility. Investors will closely monitor the company's ability to execute its strategic plan and achieve the projected second-half recovery, especially given the ongoing operational challenges and the impact of geopolitical developments.

At the time of this filing, PRGO was trading at $12.16 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $9.23 to $28.44. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

descriptionView Main SEC Filing

show_chartPrice Chart

Share this article

Copied!

feed PRGO - Latest Insights

PRGO
May 06, 2026, 4:14 PM EDT
Filing Type: 10-Q
Importance Score:
9
PRGO
May 06, 2026, 6:33 AM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
May 06, 2026, 6:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
PRGO
May 05, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
7
PRGO
Apr 30, 2026, 4:43 PM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
Apr 22, 2026, 4:47 PM EDT
Filing Type: 8-K
Importance Score:
7
PRGO
Mar 23, 2026, 4:18 PM EDT
Filing Type: 8-K
Importance Score:
8
PRGO
Mar 20, 2026, 11:33 AM EDT
Filing Type: DEF 14A
Importance Score:
8
PRGO
Feb 26, 2026, 1:34 PM EST
Filing Type: 10-K
Importance Score:
9
PRGO
Feb 26, 2026, 6:38 AM EST
Filing Type: 8-K
Importance Score:
9